Oncology drug developer OS Therapies refiles for $8M IPO (Pending:OSTX)

June 28, 2024

in Stocks

Reading Time: 1 min read

OS Therapies (OSTX) has refiled to raise $8M through a proposed initial public offering.

The oncology drug developer said in its most recent SEC filing that it was looking to offer 2M common shares priced at $4 per share. Underwriters would be granted a 45-day option to purchase up to 300K additional shares to cover any over-allotments.

Support authors and subscribe to content

This is premium stuff. Subscribe to read the entire article.

Gain access to all our Premium contents.
More than 100+ articles.

Subscribe Now

Buy Article

Unlock this article and gain permanent access to read it.

Unlock Now

Oncology drug developer OS Therapies refiles for $8M IPO (Pending:OSTX)

Related Articles

Why David Einhorn Is Buying CNH, a Cheap Stock ‘No One Cares About’

5 Charts Showing the Immense Market Impact of Trump’s Presidential Win: BofA

Oil Outlook: US Production Boom, Weak China Demand to Lead to Oversupply in 2025

Stock Market Today: Tech Leads Sell-Off As Rate-Cut Odds Fall on Powell

Inflation Outlook: 4 Signs of Re-Inflation Investors Should Watch Out for

Oppenheimer Predicts up to 740% Rally for These 2 ‘Strong Buy’ Stocks

8 Tax Loopholes to Reduce or Avoid Capital Gains Taxes

5 Signs Economy Is Heading Toward Recession — Putting Stocks at Risk

It’s a Tough Time to Be a Tech Graduate

Navigate Site

Welcome Back!

Retrieve your password

Are you sure want to unlock this post?

Are you sure want to cancel subscription?

Oncology drug developer OS Therapies refiles for $8M IPO (Pending:OSTX)

Support authors and subscribe to content

Subscribe

Buy Article

Related Articles

Navigate Site

Follow Us

Welcome Back!

Retrieve your password

Are you sure want to unlock this post?

Are you sure want to cancel subscription?